CoreCap Advisors’s Sarepta Therapeutics SRPT Stock Holding History

CoreCap Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54	Hold	3	–	–	﹤0.01%	3115
2026 Q1	$65	Hold	3	–	–	﹤0.01%	2867
2025 Q4	$65	Hold	3	–	–	﹤0.01%	2894
2025 Q3	$58	Hold	3	–	–	﹤0.01%	2751
2025 Q2	$51	Hold	3	–	–	﹤0.01%	2713
2025 Q1	$191	Sell	3 -4	-57%	-$421	﹤0.01%	2992
2024 Q4	$851	Buy	+7	New	+$858	﹤0.01%	2402

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

CoreCap Advisors's SRPT Position: Q2 2026 in Review

CoreCap Advisors held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 3 shares worth $54. The position accounts for ﹤0.01% of the portfolio, ranked #3115.

CoreCap Advisors first reported a position in SRPT in Q4 2024 and has held it in 7 quarters since. The position peaked at $851 in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

CoreCap Advisors held 3 shares of Sarepta Therapeutics worth $54 as of Q2 2026.
CoreCap Advisors left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #3115 holding.
CoreCap Advisors first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 7 quarters since.
CoreCap Advisors's Sarepta Therapeutics position peaked at $851 in Q4 2024.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.